News and Events
Precision Biologics along with Dr Christina Annunziata, MD, PhD, from the NCI are presenting at the AACR Annual Meeting
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway Session Category: Immunology Session Title: Therapeutic Antibodies, Including Engineered Antibodies...
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments December 5-7, 2017 in San Diego, CA
Dr. Philip Arlen to Speak at World Vaccine Congress Europe Topic: Targeting cancer neoantigens: A promising source of immunogens for cancer immunotherapy 10 - 12 October 2017, Crowne Plaza Hotel Barcelona - Fira Center, Barcelona
Dr. Philip Arlen to Speak at Immuno-Oncology Summit - The Summit will return to Boston on - August 28-September 1
Dr. Philip Arlen to Speak at ASCO Annual Meeting - June 2-6, 2017 | McCormick Place | Chicago, IL
May 1-5, 2017 Seaport World Trade Center Boston, MA
Monoclonal Antibodies Targeting Novel Immunogenic Neo-Epitopes for the Treatment of Solid Tumors May 2-4, 2017, Philadelphia Marriott Downtown Philadelphia, PA
Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
Rockville, MD, April 2, 2017 – Precision-Biologics Inc.
Dr. Philip Arlen to Speak at Immuno-Oncology Breakthroughs - Novel Cancer Therapies at the Noblecon 13 meeting